However , post-hoc analysis of the subgroup of patients not using chronic inhaled tobramycin showed a 5.7 % difference ( 95 % CI 1.5-10 .1 ) in relative change from baseline in percent-predicted FEV1 between the ataluren and placebo groups at week 48 ( -0.7 % [ -4.0 to 2.1 ] vs -6.4 % [ -9.8 to -3.7 ] ; nominal p = 0.0082 ) , and fewer pulmonary exacerbations in the ataluern group ( 1.42 events [ 0.9-1 .9 ] vs 2.18 events [ 1.6-2 .7 ] ; rate ratio 0.60 [ 0.42-0 .86 ] ; nominal p = 0.0061 ) .